Isaac Ciechanover, M.D.
CEO & President
Dr. Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in August 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene’s Executive Director for Business Development, he spearheaded the company’s venture capital efforts and led licensing and M&A activities with an aggregate value of more than $6.7 billion. Also at Celgene, he was Global Project Leader for the company’s first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequot Ventures’ healthcare practice and Pfizer. Intellectually curious (and undeterred by student debt), Isaac holds a B.A. from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an M.B.A. from Harvard Business School. For fun, he enjoys cycling, scuba diving and building Lego with his two children. His all-time favorite albums are Pink Floyd’s “The Dark Side of the Moon,” Radiohead’s “OK Computer” and Ruggero Leoncavallo’s Italian opera, Pagliacci, with Herbet Von Karajan conducting.
Director, Seattle Genetics, Inc.
Mr. Dobmeier is currently the Chief Operating Officer of Seattle Genetics, Inc., a biotechnology company. Mr. Dobmeier joined Seattle Genetics in March 2002 and has served in positions of increasing responsibility since then, most recently as Chief Business Officer from May 2007 to June 2011. Prior to joining Seattle Genetics, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier also serves as a director of Stemline Therapeutics, Inc., a public biotechnology company. Mr. Dobmeier received a J.D. from the University of California, Berkeley School of Law and an A.B. in History from Princeton University.
Director, Audit Committee Chair
Matthew Fust is an advisor to life sciences companies. He was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals from January 2009 through its acquisition in October 2013. From May 2003 to December 2008, Matthew served as Chief Financial Officer of Jazz Pharmaceuticals. From 2002 to 2003, he served as Chief Financial Officer of Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Matthew was a member of Andersen Consulting’s healthcare strategy practice. He received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.
Matthew is a director of Dermira, MacroGenics, and Ultragenyx Pharmaceutical.
Carol G Gallagher, Pharm.D.
Dr. Carol Gallagher serves as the Lead Independent Director of Atara Biotherapeutics. She recently joined the life sciences practice of New Enterprise Associates as a Partner. She serves as Chairman of AnaptysBio and as a Director at Millendo Therapeutics.
From 2008-2011, Carol was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. During her tenure as CEO at Calistoga Pharmaceuticals, Carol raised $80 million in venture financing and led the company to a successful exit with the acquisition by Gilead Sciences in April 2011 for $375 million and a total consideration of $600 million. Gilead continued to rapidly advance registration trials of ZYDELIG in patients with certain types of leukemia and lymphoma. In 2014, ZYDELIG was approved in the US and Europe for three indications simultaneously.
Carol studied chemistry at Vanderbilt University and then pursued a clinical background, attaining Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.
Mr. Heiden is an experienced pharmaceutical and biotechnology executive. He joined AMAG Pharmaceuticals, Inc. (AMAG) in May 2012 as president and chief executive officer. Mr. Heiden is also a member of AMAG’s board of directors. Prior to joining AMAG, Mr. Heiden served as president and chief executive officer of GTC Biotherapeutics, Inc. since June 2010. Prior to joining GTC Biotherapeutics, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals, Inc., a pharmaceutical company, from September 2004 until December 2008.
Prior to joining Elixir Pharmaceuticals, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (which was acquired by GlaxoSmithKline plc), from 2002 to 2004. From 1987 to 2002, Mr. Heiden progressed through various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. Mr. Heiden served on the board of directors of GTC Biotherapeutics, Inc., rVEO Biologics and LFB Biotechnologies S.A.S., a private French biotechnology company. Mr. Heiden holds an M.B.A. from Cornell University’s Johnson Graduate School of Management, a M.I.M. degree from the University of Louvain and a B.A. degree from the University of Florida.
Joel S. Marcus
Director, Alexandria Real Estate Equities, Inc.
Joel S. Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with $19 million in seed capital and has led its growth into an S&P 500 company with an approximately $15 billion total market capitalization and a significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In 1996, Mr. Marcus founded the company’s venture investments arm, Alexandria Venture Investments, to provide strategic investment capital to innovative life science and technology entities developing breakthrough therapies and technologies. Mr. Marcus introduced the company’s highly unique and interactive thought leadership platform in 2011, when he co-founded the renowned Alexandria Summit®, which convenes a diverse group of visionary partners and key stakeholders to address the most critical challenges in global healthcare, agriculture, and the environment.
In addition to Atara Biotherapeutics, Inc., he also serves on the boards of Applied Therapeutics Inc., (NASDAQ:ATRA), Boragen Inc., Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), MeiraGTx Limited, Yumanity Therapeutics; Biotechnology Innovation Organization (BIO), Foundation for the National Institutes of Health (FNIH), Friends of Cancer Research, NewYorkBIO, The Scripps Research Institute; the 9/11 Memorial & Museum, Partnership for New York City, and Robin Hood Foundation; as well as on NAREIT’s 2017 Executive Board. Mr. Marcus was one of the original architects and co-founders of Accelerator Corporation, for which he serves on the board of directors, and AgTech Accelerator Corporation, for which he serves as Chairman of the board. Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs. Mr. Marcus earned his undergraduate and Juris Doctor degrees from the University of California, Los Angeles, and was a recipient of the Ernst & Young Entrepreneur Of the Year Award (Los Angeles — Real Estate).
Beth Seidenberg, M.D.
Director, Kleiner Perkins Caufield & Byers
Dr. Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining KPCB in 2005, Beth has incubated five companies and also serves on the board of directors of 3-V Biosciences, Armo Biosciences, Auxogyn, Breathe Technologies, Epizyme, iPierian, FLX, Redbrick Health and TESARO.
Before joining KPCB, Beth was the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Company and Merck, Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami School of Medicine. She completed her post-graduate training at The Johns Hopkins University, George Washington University and the National Institutes of Health.